Hereditary cancer syndromes are experiments of nature which, although devastating for the affected families, have helped to illuminate genes and pathways that are important for human carcinogenesis. von Hippel-Lindau disease is a hereditary cancer syndrome caused by inactivating mutations of the VHL tumor suppressor gene and is characterized by an increased risk of a number of different tumors, including central nervous system hemangioblastomas, clear-cell renal carcinomas, and pheochromocytomas . Tumor development in this setting is due to inactivation or loss of the remaining wild-type VHL allele in a susceptible cell. In keeping with the Knudson 2-Hit model, biallelic VHL inactivation is also common in sporadic hemangioblastomas and clearcell renal carcinomas (the most common form of kidney cancer) (Kim and Kaelin 2004) . This review focuses on our current understanding of the functions of the VHL gene product, pVHL.
ISOLATION OF THE VHL GENE
Linkage studies performed in the 1980s revealed that the gene responsible for von Hippel-Lindau disease resides on chromosome 3p25, which is a region of the genome that is frequently altered in sporadic clear-cell renal carcinoma (Seizinger et al. 1988) . The VHL gene, including a partial cDNA, was isolated in 1993 by a consortium led by Berton Zbar at the National Cancer Institute (Latif et al. 1993 ). This group also confirmed the presence of intragenic VHL mutations in affected individuals from VHL families (Latif et al. 1993) . With stateof-the-art mutation detection methods, including semiquantitative Southern blot analysis (to detect the ~20% of VHL cases associated with loss of the entire VHL locus), VHL mutations can be detected in virtually every individual who carries a clinical diagnosis of VHL disease (Stolle et al. 1998) . Multiple groups have documented that VHL inactivation, due to either mutation or hypermethylation, is also common in sporadic clear-cell renal carcinomas and hemangioblastomas but rare in tumor types not seen in VHL disease (Kim and Kaelin 2004) .
The VHL gene is ubiquitously expressed and gives rise to an ~4.5-kb mRNA Renbaum et al. 1996) . This mRNA encodes two protein isoforms as a result of alternative translation initiation from two inframe start codons Schoenfeld et al. 1998; Blankenship et al. 1999 ). These two isoforms behave similarly in most biochemical and functional assays and so are often referred to generically as "pVHL".
THE VHL GENE PRODUCT, pVHL
pVHL is primarily cytosolic but shuttles to and from the nucleus in a transcription-dependent manner Lee et al. 1996 Lee et al. , 1999 Corless et al. 1997; Ye et al. 1998; Groulx and Lee 2002) . Some pVHL can also be detected in association with the endoplasmic reticulum and with mitochondria Shiao et al. 2000; Schoenfeld et al. 2001) . The best-understood function of pVHL relates to its role as a substrate adapter in a ubiquitin ligase complex that contains elongin B, elongin C, Cullin 2, and Rbx1 (Duan et al. 1995a,b; Kibel et al. 1995; Kishida et al. 1995; Pause et al. 1997 Pause et al. , 1999 Lonergan et al. 1998; Kamura et al. 1999 ). In the presence of oxygen, pVHL binds directly to the α subunits of a heterodimeric transcription factor called HIF (hypoxia-inducible factor) and directs their polyubiquitination, which earmarks them for proteasomal degradation ( Fig. 1 ) (Maxwell et al. 1999; Cockman et al. 2000; Kamura et al. 2000; Ohh et al. 2000; Tanimoto et al. 2000) . pVHL contains two mutational hot spots . One, called the α domain, nucleates the elongin/Cul2/Rbx1 complex Ohh et al. 1999) . The other, called the β domain, binds directly to HIFα (Ohh et al. 2000) .
Under low oxygen conditions, HIFα subunits accumulate, bind to specific DNA sequences (HIF-response elements or HREs) in a complex with a HIFβ subunit (such as HIF1β or ARNT), and activate the transcription of genes involved in acute or chronic adaptation to hypoxia, such as VEGF, PDGF B, and TGF-α (Semenza 2000) . In cells lacking pVHL, however, HIFα accumulates to high levels irrespective of oxygen availability, leading to overexpression of these target genes Iliopoulos et al. 1996; Siemeister et al. 1996; Stratmann et al. 1997; Maxwell et al. 1999; Krieg et al. 2000; Wykoff et al. 2000; Zatyka et al. 2002; Jiang et al. 2003) . The interaction of pVHL with HIF is oxygen-dependent because HIFα must be hydroxylated on one of two prolyl residues by members of the EglN (EglN1, 2, or 3) family of dioxygenases before it can be recognized by pVHL (Bruick and McKnight 2001; Epstein et al. 2001; Jaakkola et al. 2001; Masson et al. 2001; Yu et al. 2001) . The crystal structure of pVHL bound to a HIF1α-derived peptide has been solved and shows that two hydrophobic residues within the pVHL β domain form critical contacts with the HIF prolyl hydroxyl group (Hon et al. 2002; Min et al. 2002) .
The oxygen atom of the hydroxyl group is derived from molecular oxygen, and EglN-dependent HIF hydroxylation is sensitive to changes in oxygen over a physiologically relevant range (oxygen K m~2 00 μM) (Epstein et al. 2001; Hirsila et al. 2003) . EglN1 (also called PHD2) appears to be the primary HIF prolyl hydroxylase under resting conditions (Berra et al. 2003) , although other members of the family become important after prolonged hypoxia. In fact, EglN3 (also called PHD3) is itself a HIF target (del Peso et al. 2003; Aprelikova et al. 2004; Marxsen et al. 2004 ). EglN-dependent prolyl hydroxylation requires several cofactors, including Fe 2+ , 2-oxoglutarate, and ascorbate. Recent studies suggest that EglN activity is sensitive to changes in reactive oxygen species (ROS), perhaps through changes in iron oxidation (Gerald et al. 2004; Brunelle et al. 2005; Guzy et al. 2005; Mansfield et al. 2005 ). In addition, EglN protein abundance is regulated by members of the SIAH family, which polyubiquitinate EglN (Nakayama et al. 2004; Simon 2004) .
A number of other pVHL-binding partners have been reported, including Sp1, atypical protein kinase C members (aPKC), the CCT chaperonin complex, FIH-1 (Factor Inhibiting HIF 1), specific RNA polymerase subunits, fibronectin, microtubules, and VDU1/2 (for review, see Czyzyk-Krzeska and Meller 2004) . The functional relevance of many of these interactions is still under investigation. For example, pVHL-defective cells are defective with respect to extracellular fibronectin matrix assembly ), but whether and how this relates to pVHL's ability to bind to fibronectin remains unclear. A number of pVHL functions, including regulation of HIFresponsive enzymes that regulate matrix turnover (such as certain MMPs) (Koochekpour et al. 1999 ) and regulation of integrins (perhaps due to changes in aPKC activity) (Esteban-Barragan et al. 2002) , might indirectly affect fibronectin matrix assembly. Regulation of aPKC by pVHL is discussed in greater detail below.
ANIMAL MODELS
VHL orthologs have been described in Caenorhabditis elegans, Drosophila melanogaster, and rodents (Duan et al. 1995a; Gao et al. 1995; Kessler et al. 1995; Adryan et al. 2000; Epstein et al. 2001; Bishop et al. 2004 ). Inactivation of VHL in C. elegans and D. melanogaster leads to increased HIF levels, as expected, and in the latter is associated with abnormal development of the tracheal system (Adryan et al. 2000; Epstein et al. 2001; Bishop et al. 2004) . VHL +/-mice develop blood vessel tumors of the liver that resemble cavernous hemangiomas (Haase et al. 2001 ) (VHL -/-animals die during embryogenesis due to defective placentogenesis; Gnarra et al. 1997) . Similar liver abnormalities are also observed in mice carrying conditional VHL alleles (VHL flox/flox) when crossed to mice expressing Cre recombinase under the liver-specific albumin promoter (Haase et al. 2001; Ma et al. 2003) . Importantly, these lesions can be prevented by simultaneous inactivation of ARNT, suggesting that HIF dysregulation is necessary for the development of these lesions (Rankin et al. 2005) . So far, tumors observed in human VHL disease (CNS hemangioblastomas, clear-cell renal carcinomas, pheochromocytomas) have not been seen in VHL +/-mice or in VHL flox/flox mice in which VHL has been inactivated in various tissues using Cre recombinase under the control of an actin promoter (Haase et al. 2001; Ma et al. 2003) . This suggests that the mouse is not a permissive host for Figure 1 . Control of HIF stability by pVHL. In the presence of oxygen and the indicated cofactors, HIFα subunits are hydroxylated on either (or both) of two specific proline residues by EglN family members (EglN1 is the main HIF prolyl hydroxylase under normal conditions). Hydroxylation of either site generates a binding site for a ubiquitin ligase complex containing pVHL, which targets HIFα for degradation by the 26S proteasome. Under low-oxygen conditions, or in the absence of pVHL, HIFα accumulates and forms a heterodimer with HIFβ that is capable of transcriptionally activating genes involved in acute or chronic adaptation to hypoxia.
tumor growth in nude mouse xenograft assays can be abrogated by a HIF-2α variant that cannot be hydroxylated on proline, but not the corresponding HIF-1α variant Maranchie et al. 2002) . Finally, eliminating HIF-2α in VHL -/-renal carcinoma lines using shRNA is sufficient to suppress tumor growth in vivo Zimmer et al. 2004) . It is perhaps also noteworthy that a number of drugs that inhibit growth factors downstream of HIF (such as VEGF and PDGF B) demonstrate significant activity against human kidney cancer (Kaelin 2004) .
VHL disease can be subdivided into Type 1 (low risk of pheochromocytoma) and Type 2 (high risk of pheochromocytoma). Type 2 can be subdivided into 2A (low risk of renal cancer), 2B (high risk of renal cancer), and 2C (pheochromocytoma only) . The products of Type 1, 2A, and 2B are clearly defective with respect to HIF regulation and, in particular, differences in HIF regulation would not appear to explain the differential risk of renal carcinoma in Type 2A versus Type 2B families (Clifford et al. 2001; Hoffman et al. 2001) . It is possible that a pVHL function unrelated to HIF is differentially affected by Type 2A and 2B VHL mutations and modifies the risk of renal carcinoma. Type 2C mutants retain the ability to regulate HIF, which was a clue that a HIF-independent pVHL function might be important for pheochromocytoma development.
pVHL AND PHEOCHROMOCYTOMA
Type 2 families almost always have missense mutations, whereas true null alleles cause Type 1 disease . This suggested to us either that pheochromocytoma development is due to a pVHL gain of function or that complete loss of pVHL is not tolerated in pheochromcytoma precursor cells. Moreover, VHL mutations are rare in sporadic pheochromocytomas (in contrast to sporadic renal carcinomas and hemangioblastomas) in the absence of an occult germ-line VHL mutation (Neumann et al. 2002) . This suggested to us that VHL might play a specific role in the embryological development of primitive sympathetic neuronal precursor cells, which are the cells that give rise to pheochromocytoma.
In this regard, we recently discovered that inactivation of pVHL leads to up-regulation of JunB (Lee et al. 2005 ). This appears to be due, at least partly, to increased aPKC activity, which is known to enhance JunB transcription (Kieser et al. 1996) . Multiple groups reported earlier that pVHL inhibits aPKC family members (Pal et al. 1997; Okuda et al. 1999 Okuda et al. , 2001 ). Every pVHL mutant we have tested so far, including those linked to Type 2C disease, fails to suppress JunB (Lee et al. 2005) .
Many sympathetic neuronal progenitor cells normally die during development as they compete with one another for growth factors such as NGF (Deckwerth and Johnson 1993; Edwards and Tolkovsky 1994; Estus et al. 1994; Schlingensiepen et al. 1994; Ham et al. 1995) . Death in this setting is the result of c-Jun-dependent apoptosis. JunB often antagonizes c-Jun. We showed that loss of pVHL (and increased JunB) leads to decreased apoptosis these lesions or that the right cell type has not yet been targeted at the right time.
pVHL AND HEMANGIOBLASTOMA
Hemangioblastomas are highly vascular tumors that consist of blood vessels (and hence endothelial cells and supporting pericytes) admixed with tumor cells of unclear embryological origins (Richard et al. 1998) . Laser capture microdissection and immunohistochemistry studies have documented VHL inactivation in hemangioblastoma tumor cells leading to the overproduction of VEGF and PDGF, which support endothelial cells and pericytes, respectively, in a paracrine fashion, as well as EPO and TGF-α, which are suspected of acting as autocrine growth factors (Reifenberger et al. 1995; WizigmannVoos et al. 1995; Vortmeyer et al. 1997; Flamme et al. 1998; Chan et al. 1999) . Anecdotal evidence suggests that inhibiting the VEGF receptor KDR can help to ameliorate symptoms in this disease but has not yet led to frank tumor regressions (Aiello et al. 2002; Girmens et al. 2003; Madhusudan et al. 2004) . In mouse models of tumor angiogenesis, targeting VEGF alone is not sufficient to induce regression of established blood vessels, but instead dual blockade of both VEGF and PDGF (apparently to block survival signals provided to endothelial cells by surrounding pericytes) is needed (Benjamin et al. 1999; Bergers et al. 2003 ). It will be of interest to determine whether dual VEGF/PDGF blockade will cause regression of hemangioblastomas in man.
pVHL AND KIDNEY CANCER
pVHL inactivation can be demonstrated in preneoplastic renal cysts in VHL kidneys, suggesting that pVHL loss is an early step in renal carcinogenesis (Zhuang et al. 1995; Lubensky et al. 1996; Mandriota et al. 2002) . As described above, biallelic VHL inactivation, due to mutation or hypermethylation, is common in sporadic clearcell renal cancers. Moreover, restoration of pVHL function is sufficient to suppress tumor formation by VHL -/-clear-cell renal carcinoma lines established from sporadic tumors Gnarra et al. 1996) . Collectively, these observations suggest that VHL is a critical "gatekeeper" with respect to renal carcinogenesis. In contrast to many other tumor suppressor genes, restoration of pVHL function does not affect the growth of VHL -/-renal carcinoma lines in vitro under standard cell culture conditions. However, the growth-suppressive effects of pVHL can be revealed when cells are grown under low serum or as 3-dimensional spheroids (Lieubeau-Teillet et al. 1998; Pause et al. 1998; Davidowitz et al. 2001) .
HIF-2α is a critical target of pVHL with respect to renal carcinogenesis. First, an apparent switch from HIF-1α to HIF-2α expression occurs in preneoplastic lesions arising in VHL +/-kidneys in association with increasing dysplasia and cellular atypia (Mandriota et al. 2002) . Second, VHL -/-renal carcinoma lines either express both HIF-1α and HIF-2α or exclusively HIF-2α (Maxwell et al. 1999) . Third, the ability of pVHL to suppress VHL -/-of neuronal cells after NGF withdrawal, as does inactivation of NF-1 or activation of c-RET, both of which affect signaling by the NGF receptor TrkA and can, when mutated in the germ line, cause familial pheochromocytoma (Fig. 2) (Vogel et al. 1995; Maher and Eng 2002; Lee et al. 2005) .
Another gene implicated in apoptosis after NGF withdrawal is SM-20/EglN3, which is a paralog of the primary HIF prolyl hydroxylase EglN1 (Lipscomb et al. 1999 (Lipscomb et al. , 2001 Straub et al. 2003) . We found that EglN3 acts downstream of c-Jun and is both necessary and sufficient for apoptosis after NGF withdrawal (Fig. 2) (Lee et al. 2005) . Prolyl hydroxylation is coupled to the conversion of 2-oxoglutarate to succinate, which can then feedback-inhibit the hydroxylation reaction (Selak et al. 2005; Lee et al. 2005) . Interestingly, germ-line mutations affecting succinate dehydrogenase (SDH) subunits B, C, and D have been linked to the development of familial pheochromocytoma (and the related tumor paraganglioma) (Maher and Eng 2002) . We confirmed that SDH mutations lead to succinate accumulation and blunt EglN3-dependent neuronal apoptosis (Lee et al. 2005) . Hence our findings place all of the known pheochromocytoma genes on the same pathway and suggest that failure of normal developmental culling of sympathetic neuronal precursors is the common feature of hereditary pheochromocytoma syndromes (Figs. 2 and 3 ). This could explain why mutations in these genes are linked to pheochromocytoma only if they are present in the germ line.
EglN3, as described above, is a HIF target (Cioffi et al. 2003; del Peso et al. 2003; Aprelikova et al. 2004 ). Therefore, pVHL has both positive (via aPKC) and negative (via HIF) effects on EglN3 levels. We found that EglN3 levels are high in cells producing Type 1 pVHL mutants and low in Type 2 pVHL mutants (Lee et al. 2005) . This potentially explains the distinction between Type 1 and Type 2 VHL disease. EglN1 does not induce neuronal apoptosis and EglN3-induced apoptosis, which requires that its catalytic domain be intact, is not blocked by nonhydroxylatable versions of HIF-1 or HIF-2α (Lee et al. 2005) . This strongly argues that a hydroxylation target other than HIF links EglN3 to the induction of apoptosis.
CONCLUSIONS
The von Hippel-Lindau tumor suppressor protein is the substrate recognition unit of a ubiquitin ligase complex that targets HIF for degradation in the presence of oxygen. The interaction of pVHL with HIF is governed by prolyl hydroxylation of HIFα subunits by EglN family members. Inactivation of pVHL plays an important role in hereditary and sporadic hemangioblastomas and clearcell renal carcinomas. Deregulation of HIF target genes contributes to tumorigenesis in these settings.
Germ-line VHL mutations can also give rise to pheochromocytomas, as can germ-line NF1, c-RET, and SDH mutations. Our recent work suggests that these mutations affect a common pathway involved in developmental culling of sympathetic neuronal precursor cells upon the withdrawal of growth factors such as NGF.
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I thank the past and present members of the Kaelin laboratory who have contributed to our current understanding of VHL disease. I am grateful for support from the Howard Hughes Medical Institute, the National Institutes of Health, and the Murray Foundation. Control of neuronal apoptosis by familial pheochromocytoma genes. Pheochromocytomas are derived from the same cells that give rise to the sympathetic nervous system. These progenitors compete for growth factors such as NGF during development. NGF signals via TrkA, which suppresses the accumulation of c-Jun. Upon NGF withdrawal, c-Jun activity increases, leading to apoptosis. Gain-of-function c-RET mutations and loss-of-function VHL, NF1, and SDH (subunits B, C, or D) mutations have been linked to familial pheochromocytoma and the related tumor, paraganglioma. NF1 inhibits TrkA signaling, whereas activated c-RET stimulates TrkA activity. Loss of pVHL leads to increased JunB accumulation (in part due to aPKC dysregulation), which blunts c-Jun action. SDH inactivation leads to the accumulation of succinate, which inhibits the activity of EglN3. EglN3 acts downstream of c-Jun and induces neuronal apoptosis in a seemingly HIF-independent manner. Therefore, all known familial pheochromocytoma alleles would be predicted to attenuate developmental neuronal apoptosis. Familial pheochromocytoma alleles would be predicted to allow some of these cells to escape apoptosis (red square, bottom) (see also Fig. 2 ). These persistent cells might fail to form normal cell-cell or cell-matrix interactions. This, in conjunction with additional somatic mutations, is envisioned to result in pheochromocytoma.
